

Arnaud Jaccard

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1001163/publications.pdf>

Version: 2024-02-01

136
papers

9,778
citations

41344

49
h-index

38395

95
g-index

153
all docs

153
docs citations

153
times ranked

9158
citing authors

#	ARTICLE	IF	CITATIONS
1	New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes. <i>Journal of Clinical Oncology</i> , 2012, 30, 4541-4549.	1.6	735
2	High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis. <i>New England Journal of Medicine</i> , 2007, 357, 1083-1093.	27.0	473
3	Infections in 252 Patients with Common Variable Immunodeficiency. <i>Clinical Infectious Diseases</i> , 2008, 46, 1547-1554.	5.8	394
4	Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. <i>Blood</i> , 2006, 107, 3053-3057.	1.4	390
5	Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. <i>Lancet Oncology</i> , The, 2012, 13, 196-206.	10.7	349
6	Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. <i>Blood</i> , 2011, 117, 1834-1839.	1.4	346
7	Determinants of Disease Presentation and Outcome during Cryptococcosis: The CryptoA/D Study. <i>PLoS Medicine</i> , 2007, 4, e21.	8.4	338
8	The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. <i>Nature Reviews Nephrology</i> , 2019, 15, 45-59.	9.6	330
9	Intensive Chemotherapy Followed by Hematopoietic Stem-Cell Rescue for Refractory and Recurrent Primary CNS and Intraocular Lymphoma: Soci�t� Fran�saise de Greffe de Mo�lle Osseuse-Th�rapie Cellulaire. <i>Journal of Clinical Oncology</i> , 2008, 26, 2512-2518.	1.6	301
10	Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. <i>Blood</i> , 2018, 132, 2456-2464.	1.4	301
11	A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. <i>Lancet Oncology</i> , The, 2016, 17, 389-400.	10.7	285
12	Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. <i>New England Journal of Medicine</i> , 2021, 385, 46-58.	27.0	268
13	VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial. <i>Blood</i> , 2016, 127, 2569-2574.	1.4	224
14	AL Amyloidosis. <i>Orphanet Journal of Rare Diseases</i> , 2012, 7, 54.	2.7	199
15	Cardiac amyloidosis: Updates in diagnosis and management. <i>Archives of Cardiovascular Diseases</i> , 2013, 106, 528-540.	1.6	181
16	Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications. <i>Blood</i> , 2018, 132, 1478-1485.	1.4	173
17	Denosumab for Treatment of Hypercalcemia of Malignancy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 3144-3152.	3.6	157
18	Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection. <i>Blood</i> , 2016, 128, 2527-2532.	1.4	149

#	ARTICLE	IF	CITATIONS
19	Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. <i>Blood</i> , 2020, 136, 71-80.	1.4	146
20	Disseminated Microsporidiosis Due To <i>Septata intestinalis</i> In Patients With AIDS: Clinical Features And Response To Albendazole Therapy. <i>Journal of Infectious Diseases</i> , 1995, 171, 245-249.	4.0	145
21	Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network. <i>Neuro-Oncology</i> , 2016, 18, 1297-1303.	1.2	135
22	Results From a Prospective, Open-Label, Phase II Trial of Bendamustine in Refractory or Relapsed T-Cell Lymphomas: The BENTLY Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 104-110.	1.6	134
23	High-dose therapy and autologous blood stem cell transplantation in POEMS syndrome. <i>Blood</i> , 2002, 99, 3057-3059.	1.4	131
24	Granulomatous Disease in CVID: Retrospective Analysis of Clinical Characteristics and Treatment Efficacy in a Cohort of 59 Patients. <i>Journal of Clinical Immunology</i> , 2013, 33, 84-95.	3.8	125
25	Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study. <i>Blood</i> , 2010, 116, 4777-4782.	1.4	118
26	Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naive patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III). <i>Haematologica</i> , 2014, 99, 1479-1485.	3.5	118
27	L-Asparaginase-based treatment of 15 western patients with extranodal NK/T-cell lymphoma and leukemia and a review of the literature. <i>Annals of Oncology</i> , 2009, 20, 110-116.	1.2	111
28	Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2019, 37, 1657-1665.	1.6	111
29	A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. <i>Blood</i> , 2017, 130, 597-605.	1.4	108
30	Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease. <i>Kidney International</i> , 2015, 88, 1135-1143.	5.2	104
31	Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis. <i>Journal of Clinical Oncology</i> , 2020, 38, 3252-3260.	1.6	102
32	A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis. <i>Blood</i> , 2020, 135, 1531-1540.	1.4	94
33	Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?. <i>Blood</i> , 2015, 126, 2713-2719.	1.4	92
34	Prevention of Infections During Primary Immunodeficiency. <i>Clinical Infectious Diseases</i> , 2014, 59, 1462-1470.	5.8	81
35	Hepatitis C virus and Sjögren's syndrome. <i>Arthritis and Rheumatism</i> , 1993, 36, 280-281.	6.7	78
36	Randall-type monoclonal immunoglobulin deposition disease: novel insights from a nationwide cohort study. <i>Blood</i> , 2019, 133, 576-587.	1.4	78

#	ARTICLE	IF	CITATIONS
37	The Clinical Spectrum of IgM-Related Amyloidosis. <i>Medicine (United States)</i> , 2008, 87, 99-109.	1.0	73
38	Kidney Diseases Associated With Monoclonal Immunoglobulin Mâ€“Secreting B-Cell Lymphoproliferative Disorders: A Case Series of 35 Patients. <i>American Journal of Kidney Diseases</i> , 2015, 66, 756-767.	1.9	68
39	Unravelling the immunopathological mechanisms of heavy chain deposition disease with implications for clinical management. <i>Kidney International</i> , 2017, 91, 423-434.	5.2	66
40	Loss of the ex vivo but not the reinducible CD8+ T-cell response to Tax in human T-cell leukemia virus type 1-infected patients with adult T-cell leukemia/lymphoma. <i>Leukemia</i> , 2004, 18, 126-132.	7.2	63
41	European Collaborative Study Defining Clinical Profile Outcomes and Novel Prognostic Criteria in Monoclonal Immunoglobulin Mâ€“Related Light Chain Amyloidosis. <i>Journal of Clinical Oncology</i> , 2016, 34, 2037-2045.	1.6	60
42	Efficacy of lenalidomide in <sc>POEMS</sc> syndrome: A retrospective study of 20 patients. <i>American Journal of Hematology</i> , 2013, 88, 207-212.	4.1	59
43	<sc>HCV</sc>â€“associated <sc>B</sc>â€“cell nonâ€“<sc>H</sc>odgkin lymphomas and new direct antiviral agents. <i>Liver International</i> , 2015, 35, 2222-2227.	3.9	58
44	Low Circulating Natural Killer Cell Counts are Associated With Severe Disease in Patients With Common Variable Immunodeficiency. <i>EBioMedicine</i> , 2016, 6, 222-230.	6.1	58
45	HODGKIN'S DISEASE AFTER TRANSPLANTATION1. <i>Transplantation</i> , 1996, 61, 71-76.	1.0	57
46	Efficiency of immunoglobulin G replacement therapy in common variable immunodeficiency: correlations with clinical phenotype and polymorphism of the neonatal Fc receptor. <i>Clinical and Experimental Immunology</i> , 2013, 171, 186-194.	2.6	55
47	Identification of prognostic markers in transthyretin and AL cardiac amyloidosis*. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2016, 23, 194-202.	3.0	54
48	Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis. <i>Blood Cancer Journal</i> , 2021, 11, 10.	6.2	53
49	18F-FDG PET/CT in patients with amyloid light-chain amyloidosis: case-series and literature review. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2012, 19, 94-98.	3.0	52
50	Current anti-myeloma therapies in renal manifestations of monoclonal light chain-associated Fanconi syndrome: a retrospective series of 49 patients. <i>Leukemia</i> , 2017, 31, 123-129.	7.2	52
51	International Prognostic Index, Type of Transplant and Response to Rituximab Are Key Parameters to Tailor Treatment in Adults With CD20-Positive B Cell PTLN: Clues From the PTLN-1 Trial. <i>American Journal of Transplantation</i> , 2015, 15, 1091-1100.	4.7	48
52	del(17p) without <i>TP53</i> mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma. <i>Blood</i> , 2021, 137, 1192-1195.	1.4	48
53	Left atrial size is an independent predictor of overall survival in patients with primary systemic amyloidosis. <i>Archives of Cardiovascular Diseases</i> , 2011, 104, 611-618.	1.6	47
54	INFLUENCE OF HOST-RECIPIENT ORIGIN ON CLINICAL ASPECTS OF POSTTRANSPLANTATION LYMPHOPROLIFERATIVE DISORDERS IN KIDNEY TRANSPLANTATION. <i>Transplantation</i> , 2002, 73, 265-271.	1.0	43

#	ARTICLE	IF	CITATIONS
55	T-cell Therapy Using a Bank of EBV-specific Cytotoxic T Cells. <i>Journal of Immunotherapy</i> , 2014, 37, 170-179.	2.4	42
56	Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk. <i>Haematologica</i> , 2020, 105, e480-483.	3.5	42
57	Heart transplantation in systemic (AL) amyloidosis: A retrospective study of eight French patients. <i>Archives of Cardiovascular Diseases</i> , 2008, 101, 523-532.	1.6	37
58	Differential Expression of Neurotensin and Specific Receptors, NTSR1 and NTSR2, in Normal and Malignant Human B Lymphocytes. <i>Journal of Immunology</i> , 2012, 189, 5293-5303.	0.8	36
59	Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma. <i>Haematologica</i> , 2016, 101, 363-370.	3.5	33
60	Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays. <i>Clinical Chemistry and Laboratory Medicine</i> , 2017, 55, 1734-1743.	2.3	33
61	Left atrial function in patients with light chain amyloidosis: A transthoracic 3D speckle tracking imaging study. <i>Journal of Cardiology</i> , 2018, 71, 419-427.	1.9	33
62	Involvement of Human Herpesvirus-6 Variant B in Classic Hodgkin's Lymphoma via DR7 Oncoprotein. <i>Clinical Cancer Research</i> , 2010, 16, 4711-4721.	7.0	32
63	CD68-positive tumor-associated macrophages predict unfavorable treatment outcomes in classical Hodgkin lymphoma in correlation with interim fluorodeoxyglucose-positron emission tomography assessment. <i>Leukemia and Lymphoma</i> , 2015, 56, 332-341.	1.3	32
64	Prognostic value of left atrial function in systemic light-chain amyloidosis: a cardiac magnetic resonance study. <i>European Heart Journal Cardiovascular Imaging</i> , 2016, 17, 961-969.	1.2	32
65	HHV-6 and EBV DNA quantitation in lymph nodes of 86 patients with Hodgkin's lymphoma. <i>Journal of Medical Virology</i> , 2007, 79, 1349-1356.	5.0	30
66	Non-invasive detection of hepatic amyloidosis: FibroScan, a new tool. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2011, 18, 19-24.	3.0	29
67	Immunoglobulin variable domain high-throughput sequencing reveals specific novel mutational patterns in POEMS syndrome. <i>Blood</i> , 2020, 135, 1750-1758.	1.4	29
68	Extranodal natural killer/T-cell lymphoma. <i>Current Opinion in Oncology</i> , 2011, 23, 429-435.	2.4	28
69	Cost savings of home bortezomib injection in patients with multiple myeloma treated by a combination care in Outpatient Hospital and Hospital care at Home. <i>Supportive Care in Cancer</i> , 2016, 24, 5007-5014.	2.2	27
70	Randomized Trial Comparing Double Versus Triple Bortezomib-Based Regimen in Patients With Multiple Myeloma and Acute Kidney Injury Due to Cast Nephropathy. <i>Journal of Clinical Oncology</i> , 2020, 38, 2647-2657.	1.6	24
71	Diagnostic score of cardiac involvement in AL amyloidosis. <i>European Heart Journal Cardiovascular Imaging</i> , 2020, 21, 542-548.	1.2	23
72	Cytogenetic study of 30 patients with multiple myeloma: comparison of 3 and 6 day bone marrow cultures stimulated or not with cytokines by using a miniaturized karyotypic method. <i>British Journal of Haematology</i> , 1997, 96, 594-600.	2.5	22

#	ARTICLE	IF	CITATIONS
73	A GEIL flow cytometry consensus proposal for quantification of plasma cells: Application to differential diagnosis between MGUS and myeloma. <i>Cytometry Part B - Clinical Cytometry</i> , 2011, 80B, 176-185.	1.5	22
74	Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2023, 30, 3-17.	3.0	22
75	Polymyositis and chronic graft-versus-host disease: Efficacy of intravenous gammaglobulin. <i>Journal of the American Academy of Dermatology</i> , 1993, 28, 492-493.	1.2	20
76	Value of Nerve Biopsy in Patients With Latent Malignant Hemopathy and Peripheral Neuropathy. <i>Medicine (United States)</i> , 2015, 94, e394.	1.0	20
77	Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17p. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e493-e499.	0.4	20
78	Chlorambucil-Associated Pneumonitis. <i>Chest</i> , 1994, 105, 634-636.	0.8	19
79	Comprehensive Epstein-Barr Virus Transcriptome by RNA-Sequencing in Angioimmunoblastic T Cell Lymphoma (AITL) and Other Lymphomas. <i>Cancers</i> , 2021, 13, 610.	3.7	19
80	Pathology of Nerve Biopsy and Diagnostic Yield of PCR-Based Clonality Testing in Neurolymphomatosis. <i>Journal of Neuropathology and Experimental Neurology</i> , 2018, 77, 769-781.	1.7	18
81	Pharmacokinetics, safety, and efficacy of lenalidomide plus dexamethasone in patients with multiple myeloma and renal impairment. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 173-182.	2.3	17
82	Persistent parvovirus B19 infection and pure red cell aplasia in waldenström's macroglobulinemia: Successful treatment with high-dose intravenous immunoglobulin. <i>American Journal of Hematology</i> , 1995, 50, 227-228.	4.1	16
83	Very low levels of surface CD45 reflect CLL cell fragility, are inversely correlated with trisomy 12 and are associated with increased treatment-free survival. <i>American Journal of Hematology</i> , 2013, 88, 747-753.	4.1	16
84	Clinicopathological spectrum of renal parenchymal involvement in B-cell lymphoproliferative disorders. <i>Kidney International</i> , 2019, 96, 94-103.	5.2	16
85	POEMS Syndrome. <i>Hematology/Oncology Clinics of North America</i> , 2018, 32, 141-151.	2.2	15
86	Aggressive systemic mastocytosis. <i>Joint Bone Spine</i> , 2003, 70, 64-66.	1.6	13
87	Successful heart transplantation following melphalan plus dexamethasone therapy in systemic AL amyloidosis. <i>Haematologica</i> , 2008, 93, e32-e35.	3.5	13
88	Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter study. <i>Oncotarget</i> , 2016, 7, 85573-85583.	1.8	13
89	Lenalidomide Therapy in Nine Patients with POEMS Syndrome.. <i>Blood</i> , 2009, 114, 3872-3872.	1.4	13
90	Clonal deleted latent membrane protein 1 variants of Epstein-Barr virus are predominant in European extranodal NK/T lymphomas and disappear during successful treatment. <i>International Journal of Cancer</i> , 2016, 139, 793-802.	5.1	12

#	ARTICLE	IF	CITATIONS
91	Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study. <i>Annals of Hematology</i> , 2021, 100, 2529-2539.	1.8	12
92	Cytopenia and fludarabine. <i>Lancet</i> , The, 1993, 342, 1049-1050.	13.7	11
93	RNA-based immunoglobulin repertoire sequencing is a new tool for the management of monoclonal gammopathy of renal (kidney) significance. <i>Kidney International</i> , 2022, 101, 331-337.	5.2	11
94	BDNF belongs to the nurse-like cell secretome and supports survival of B chronic lymphocytic leukemia cells. <i>Scientific Reports</i> , 2020, 10, 12572.	3.3	10
95	PROGNOSIS OF ACQUIRED HEMOPHILIA IN OLDER PEOPLE. <i>Journal of the American Geriatrics Society</i> , 2008, 56, 956-958.	2.6	9
96	A major turning point in NK/T-cell lymphoma?. <i>Blood</i> , 2017, 129, 2342-2343.	1.4	9
97	A case of POEMS syndrome treated by autologous hematopoietic stem-cell transplantation. <i>Nature Clinical Practice Neurology</i> , 2008, 4, 686-691.	2.5	8
98	T/B ratio does not reflect levels of ZAP70 expression in clonal CLL B cells due to ZAP70 overexpression in patient T cells. <i>Cytometry Part B - Clinical Cytometry</i> , 2013, 84B, 125-132.	1.5	8
99	Hepatocyte growth factor measurement in AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2015, 22, 112-116.	3.0	8
100	Lower respiratory tract amyloidosis: Presentation, survival and prognostic factors. A multicenter consecutive case series. <i>American Journal of Hematology</i> , 2019, 94, 1214-1226.	4.1	8
101	Left ventricular assessment in patients with systemic light chain amyloidosis: a 3-dimensional speckle tracking transthoracic echocardiographic study. <i>International Journal of Cardiovascular Imaging</i> , 2019, 35, 845-854.	1.5	8
102	Campylobacter infection in adult patients with primary antibody deficiency. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 1038-1041.e4.	3.8	7
103	Immunoglobulin light chain toxicity in a mouse model of monoclonal immunoglobulin light-chain deposition disease. <i>Blood</i> , 2020, 136, 1645-1656.	1.4	7
104	An appraisal of the frequency and severity of noninfectious manifestations in primary immunodeficiencies: A study of a national retrospective cohort of 1375 patients over 10 years. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 2116-2125.	2.9	7
105	Detection of Functional Platelet-Activating Factor Receptors on Leukemic B Cells of Chronic Lymphocytic Leukemic Patients. <i>Leukemia and Lymphoma</i> , 2004, 45, 515-518.	1.3	6
106	Blood stem cell transplantation to treat cystic lung light chain deposition disease. <i>European Respiratory Journal</i> , 2015, 46, 1199-1202.	6.7	6
107	Thalidomide and POEMS syndrome: a cautious step forward. <i>Lancet Neurology</i> , The, 2016, 15, 1104-1105.	10.2	6
108	AA amyloidosis complicating monoclonal gammopathies, an unusual feature validating the concept of "monoclonal gammopathy of inflammatory significance". <i>International Journal of Clinical Practice</i> , 2021, 75, e14817.	1.7	6

#	ARTICLE	IF	CITATIONS
109	Sequential Treatment with Rituximab and CHOP Chemotherapy in B-Cell PTLD - Moving Forward to a First Standard of Care: Results From a Prospective International Multicenter Trial.. Blood, 2009, 114, 100-100.	1.4	6
110	Bladder Neuropathy and Gastric Paralysis in Polyarteritis Nodosa Associated with Hepatitis B Virus. Scandinavian Journal of Rheumatology, 1990, 19, 442-443.	1.1	5
111	Metabolic phenotype in an AL amyloidosis transgenic mouse model. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 40-41.	3.0	5
112	Short- and long-term outcomes of AL amyloidosis patients admitted into intensive care units. British Journal of Haematology, 2016, 174, 868-875.	2.5	5
113	Normal serum protein electrophoresis and mutated IGHV genes detect very slowly evolving chronic lymphocytic leukemia patients. Cancer Medicine, 2018, 7, 2621-2628.	2.8	5
114	Outcome after hematopoietic stem cell transplantation in patients with extranodal natural killer/T-cell lymphoma, nasal type: A French study from the Soci�t� Francophone de Greffe de Moelle et de Th�rapie Cellulaire (SFGM�TC). American Journal of Hematology, 2021, 96, 834-845.	4.1	5
115	Evaluation of BC-3 and BCP-1 cell lines in immunofluorescence assay to detect HHV-8 antibodies in Kaposi's sarcoma, multiple myeloma and other groups. Journal of Clinical Virology, 1999, 12, 221-231.	3.1	4
116	Amyloses. EMC - Hematologie, 2004, 1, 46-58.	0.1	4
117	Baseline differential blood count and prognosis in CD20-positive post-transplant lymphoproliferative disorder in the prospective PTLD-1 trial. Leukemia, 2013, 27, 2102-2105.	7.2	4
118	Comparison of echocardiographic parameters in Fabry cardiomyopathy and light chain cardiac amyloidosis. Echocardiography, 2018, 35, 1755-1763.	0.9	4
119	Presence of Membrane Platelet-activating Factor Receptors on B Cells of Chronic B Cell Leukaemia Patients. Leukemia and Lymphoma, 2003, 44, 1087-1088.	1.3	3
120	Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone � daratumumab: Results from the ANDROMEDA study. American Journal of Hematology, 2022, 97, 719-730.	4.1	3
121	Chapter 12 Renal Disease in Cryoglobulinemic Vasculitis. Handbook of Systemic Autoimmune Diseases, 2007, 7, 215-239.	0.1	2
122	Neuroarthropathy of the foot revealing primary systemic amyloidosis: case report and literature review. Clinical Rheumatology, 2016, 35, 535-539.	2.2	2
123	Pharmacokinetics, Efficacy and Safety of Lenalidomide (Len) in Myeloma Patients with Renal Impairment: Results From the Prospective Study �REVIR�. Blood, 2011, 118, 2934-2934.	1.4	2
124	News in the treatment of AL amyloidosis. Hematologie, 2012, 18, 116-123.	0.0	1
125	Reply to S. Girnius et al. Journal of Clinical Oncology, 2013, 31, 2750-2751.	1.6	1
126	Monoclonal IgM and neuropathy: not always anti-MAG. Blood, 2020, 136, 2366-2367.	1.4	1

#	ARTICLE	IF	CITATIONS
127	Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma. <i>Leukemia</i> , 2022, 36, 881-884.	7.2	1
128	Prognostic Value of the Different MMSET Gene Breakpoints and Correlation with Immunoglobulin Isotype and FGFR3 Expression in 173 Patients with t(4;14) Multiple Myeloma. <i>Blood</i> , 2012, 120, 3971-3971.	1.4	1
129	Treatment and Outcome of 267 Patients with IgM-Related AL Amyloidosis. <i>Blood</i> , 2012, 120, 4074-4074.	1.4	1
130	Mastocytose syst�mique agressive: � propos d�un cas. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2003, 70, 71-74.	0.0	0
131	Renal involvement in multiple myeloma and monoclonal gammopathies. <i>Hematologie</i> , 2011, 17, 342-356.	0.0	0
132	Left ventricular and atrial function in systemic light chains amyloidosis: an echocardiography and cardiac magnetic resonance comparison. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2015, 17, .	3.3	0
133	Is there still a place for autologous stem cell transplantation in systemic AL amyloidosis with severe renal disease?. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1199-1202.	0.7	0
134	Light chain lambda myeloma with fatal AL cardiac amyloidosis in a 21�year�old patient: A case report and review. <i>Clinical Case Reports (discontinued)</i> , 2019, 7, 1171-1177.	0.5	0
135	A Multicenter Phase I/II Dose Escalation Study of Lenalidomide in Combination with Melphalan and Dexamethasone in Subjects with Newly-Diagnosed Light-Chain (AL)-Amyloidosis.. <i>Blood</i> , 2008, 112, 1732-1732.	1.4	0
136	Achievement a Negative 18-FDG/PET Status at the End of Procedure by Tailored Treatment According Pre-Transplantation Pet Status in Lymphomas Improve 5 Years-OS and EFS.. <i>Blood</i> , 2008, 112, 2193-2193.	1.4	0